Company intelligence / Profile preview

VERAXA Biotech

Heidelberg, Baden-Württemberg, Germanyveraxa.com ↗

Ownership: Private
Employees: ~32
Development stage: Phase 1

Overview

VERAXA’s lead asset, VX-A901, is an Fc-enhanced therapeutic antibody targeting FLT3. It has shown potent anti-cancer activity and promising safety/tolerability in early-phase clinical trials for AML, including efficacy signals even in heavily pre-treated patients. The broader pipeline includes nine discovery/development programs across various solid and hematologic cancers

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateMonoclonal antibodyBispecific monoclonal antibodyT cell engager (TCE)
Industry: Biotech

Drug pipeline

18 assets

FLYSYN

17 more assets in the full pipeline.

Request access →

Partnerships

OmniAbEuropean Molecular Biology Laboratory ("EMBL")EMBLEM

Beyond the preview

Go deeper on VERAXA Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VERAXA Biotech.

Explore the full profile